Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog - PubMed (original) (raw)
Effects of nafazatrom and indomethacin on experimental myocardial ischemia in the anesthetized dog
V B Fiedler et al. J Cardiovasc Pharmacol. 1985 Sep-Oct.
Abstract
The anti-ischemic effects of nafazatrom (10 mg/kg intraduodenally) have been studied in a canine model of myocardial infarction. Nafazatrom was given 30 min before and 2 h after occlusion of the left anterior descending coronary artery (LAD). Effects were compared with those after intravenous indomethacin (10 mg/kg) treatment. Infarct size was measured at 6 h of coronary occlusion by postmortem tetrazolium staining. Myocardial ischemia was reduced after nafazatrom administration, whether related to total left ventricle (18 +/- 3.3 vs. 30.7 +/- 4.8%; p less than 0.05) or to the LAD vessel area at risk for infarction (51.4 +/- 4.0 vs. 82.5 +/- 4.5%; p less than 0.01). Salvage with nafazatrom occurred in the subepicardial and endomural tissues without lateral protection. Indomethacin had no effects on infarction. The LAD occlusion-induced hemodynamic consequences were reduced at 15 min by nafazatrom and remained unchanged by indomethacin. During the following experimental course, no differences were noted between the groups. At 6 h, blood flow in the nonoccluded circumflex artery increased by 12.6 +/- 3.2 ml/min (p less than 0.05) following nafazatrom treatment. Thus, nafazatrom reduced ischemia by a mechanism unrelated to changes in hemodynamics. Most likely, this was due to 5-lipoxygenase inhibition. This may shift arachidonic acid metabolism to cyclooxygenase products and prevent release of deleterious lipoxygenase products by neutrophils during ischemic injury.
Similar articles
- Nafazatrom-induced salvage of ischemic myocardium in anesthetized dogs is mediated through inhibition of neutrophil function.
Bednar M, Smith B, Pinto A, Mullane KM. Bednar M, et al. Circ Res. 1985 Jul;57(1):131-41. doi: 10.1161/01.res.57.1.131. Circ Res. 1985. PMID: 2988818 - Beneficial effects of nafazatrom on ischemic reperfused myocardium.
Shea MJ, Murtagh JJ, Jolly SR, Abrams GD, Pitt B, Lucchesi BR. Shea MJ, et al. Eur J Pharmacol. 1984 Jun 15;102(1):63-70. doi: 10.1016/0014-2999(84)90338-8. Eur J Pharmacol. 1984. PMID: 6479219 - Reduction of acute myocardial ischemia in rabbit hearts by nafazatrom.
Fiedler VB. Fiedler VB. J Cardiovasc Pharmacol. 1984 Mar-Apr;6(2):318-24. doi: 10.1097/00005344-198403000-00017. J Cardiovasc Pharmacol. 1984. PMID: 6200722 - Effects of calcium-channel blockers on myocardial preservation during experimental acute myocardial infarction.
Reimer KA, Jennings RB. Reimer KA, et al. Am J Cardiol. 1985 Jan 25;55(3):107B-115B. doi: 10.1016/0002-9149(85)90619-8. Am J Cardiol. 1985. PMID: 3881903 Review. - Mechanism of action of nafazatrom.
Seuter F, Busse WD. Seuter F, et al. Thromb Res Suppl. 1983;4:75-80. doi: 10.1016/0049-3848(83)90361-4. Thromb Res Suppl. 1983. PMID: 6415860 Review. No abstract available.
Cited by
- Blockade of TRPM7 channel activity and cell death by inhibitors of 5-lipoxygenase.
Chen HC, Xie J, Zhang Z, Su LT, Yue L, Runnels LW. Chen HC, et al. PLoS One. 2010 Jun 17;5(6):e11161. doi: 10.1371/journal.pone.0011161. PLoS One. 2010. PMID: 20567598 Free PMC article. - Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction.
Abueid L, Uslu Ü, Cumbul A, Velioğlu Öğünç A, Ercan F, Alican İ. Abueid L, et al. Anatol J Cardiol. 2017 Apr;17(4):269-275. doi: 10.14744/AnatolJCardiol.2016.7248. Epub 2016 Nov 10. Anatol J Cardiol. 2017. PMID: 27849187 Free PMC article.